| Description |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| PMS Pharma |
Letrozole 2.5mg |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Pertuzumab 420mg/14ml |
| Product Type |
Product Size |
| Injection
|
1'S |
| Product Company |
| Helix pharma
|
Doxorubicin 50mg/25ml
|
| Product Type |
Product Size |
| Injection
|
1'S |
| Product Company |
| Helix pharma
|
100mg/5ml
|
| Product Type |
Product Size |
| Tablet |
60'S |
| Product Company |
| Pharma Solution |
Sorafenib 500mg |
| Content | Letrozole is a medicine used for treating breast cancer. It can also help prevent breast cancer coming back. It is mainly prescribed for women who have been through the menopause and have a type of cancer called "hormone-dependent" breast cancer.
| Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2. Cancer cells need this enzyme to divide and grow.
| Etoposide is a podophyllotoxin derivative used to treat testicular and small cell lung tumors.
| Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
|
Reviews
There are no reviews yet.